Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Christian, Hesslinger"'
Autor:
Ross Summer, Jamie L. Todd, Megan L. Neely, L. Jason Lobo, Andrew Namen, L. Kristin Newby, Shirin Shafazand, Sally Suliman, Christian Hesslinger, Sascha Keller, Thomas B. Leonard, Scott M. Palmer, Olga Ilkayeva, Michael J. Muehlbauer, Christopher B. Newgard, Jesse Roman
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background The circulating metabolome, reflecting underlying cellular processes and disease biology, has not been fully characterized in patients with idiopathic pulmonary fibrosis (IPF). We evaluated whether circulating levels of metabolite
Externí odkaz:
https://doaj.org/article/15b5c1581a9148c1af3a23b566f2b730
Autor:
Peifeng Ruan, Jamie L Todd, Hongyu Zhao, Yi Liu, Richard Vinisko, Julia F. Soellner, Ramona Schmid, Robert J. Kaner, Tracy R. Luckhardt, Megan L. Neely, Imre Noth, Mary Porteous, Rishi Raj, Zeenat Safdar, Mary E Strek, Christian Hesslinger, Scott M. Palmer, Thomas B. Leonard, Margaret L. Salisbury
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-12 (2023)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of extracellular matrix in the pulmonary interstitium and progressive functional decline. We hypothesized that integration of multi-omics data would identify
Externí odkaz:
https://doaj.org/article/54fbde245d2043679df55023d84fe8fb
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/c2991cd5f51446e6bd20fb090904310c
Autor:
Luca Richeldi, Arata Azuma, Vincent Cottin, Christian Hesslinger, Susanne Stowasser, Claudia Valenzuela, Marlies S Wijsenbeek, Donald F Zoz, Florian Voss, Toby M Maher
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 1 (2022)
What is this summary about? This plain language summary describes the main findings from a trial in people with idiopathic pulmonary fibrosis (also called IPF) that was recently published in the New England Journal of Medicine. IPF is a rare disease
Externí odkaz:
https://doaj.org/article/2eefb79f4d8a4ee6a4bb83784b1ecb51
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Graphical Abstract
Externí odkaz:
https://doaj.org/article/f7e67c804d6e4dd18800950ecdf42f27
Autor:
Jamie L. Todd, Richard Vinisko, Yi Liu, Megan L. Neely, Robert Overton, Kevin R. Flaherty, Imre Noth, L. Kristin Newby, Joseph A. Lasky, Mitchell A. Olman, Christian Hesslinger, Thomas B. Leonard, Scott M. Palmer, John A. Belperio, on behalf of the IPF-PRO Registry investigators
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study aimed to determine the
Externí odkaz:
https://doaj.org/article/e7f3bff0a88945d383d884e06a0c2594
Autor:
Jamie L. Todd, Megan L. Neely, Robert Overton, Katey Durham, Mridu Gulati, Howard Huang, Jesse Roman, L. Kristin Newby, Kevin R. Flaherty, Richard Vinisko, Yi Liu, Janine Roy, Ramona Schmid, Benjamin Strobel, Christian Hesslinger, Thomas B. Leonard, Imre Noth, John A. Belperio, Scott M. Palmer, on behalf of the IPF-PRO Registry investigators
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-13 (2019)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which diagnosis and management remain challenging. Defining the circulating proteome in IPF may identify targets for biomarker development. We sought to quantif
Externí odkaz:
https://doaj.org/article/e7e9aa1e37874cbe8ab7871c8f6fedf1
Autor:
Kevin R. Flaherty, Timothy P.M. Whelan, Jesse Roman, Nishant Gupta, David J. Lederer, Yolanda Mageto, Maryl Kreider, Paul Sachs, Hyun J Kim, Joseph A. Lasky, Imre Noth, Ramona Schmid, Sally Suliman, Zeenat Safdar, Mridu Gulati, Christian Hesslinger, Prema Menon, L. Kristin Newby, Robert Overton, Andrew Namen, Leann Silhan, Lake Morrison, Thomas Leonard, John A. Belperio, Marilyn K. Glassberg, Albert Baker, Daniel A. Culver, Scott M. Palmer, Francis Cordova, Rishi Raj, Scott Beegle, Benjamin Strobel, Justin M. Oldham, Mary E. Strek, Tristan J. Huie, Daniel F. Dilling, Jamie L. Todd, Robert J. Kaner, Richard Vinisko, David Hotchkin, Lisa Lancaster, Timothy Liesching, Barry Sigal, Jason Lobo, Kalpalatha Guntupalli, Yi Liu, Megan L. Neely, Joao A. de Andrade, Amy Hajari Case, Doug Lee, Randolph J. Lipchik, Katey Durham, Rajat Walia, Murali Ramaswamy, Tonya D. Russell, Howard J. Huang, Jeremy Tabak, Wael Asi, Rany Condos, Janine Roy
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-13 (2019)
Respiratory Research
Respiratory Research
Background Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which diagnosis and management remain challenging. Defining the circulating proteome in IPF may identify targets for biomarker development. We sought to quantify the cir
Publikováno v:
Frontiers in pharmacology. 13
The anti-inflammatory and immunomodulatory abilities of oral selective phosphodiesterase 4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast for use in chronic obstructive pulmonary disease and psoriasis/psoriatic arthritis, respec
Autor:
Jamie L, Todd, Megan L, Neely, Robert, Overton, Hillary, Mulder, Jesse, Roman, Joseph A, Lasky, Joao A, de Andrade, Mridu, Gulati, Howard, Huang, Thomas B, Leonard, Christian, Hesslinger, Imre, Noth, John A, Belperio, Kevin R, Flaherty, Scott M, Palmer
Publikováno v:
Lung. 200(1)
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease with a variable clinical course. Biomarkers that predict patient outcomes are needed. We leveraged data from 300 patients in the multicenter IPF-PRO Registry to determi